177 related articles for article (PubMed ID: 38573331)
1. Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer.
Struebing A; McKibbon C; Ruan H; Mackay E; Dennis N; Velummailum R; He P; Tanaka Y; Xiong Y; Springford A; Rosenlund M
J Comp Eff Res; 2024 May; 13(5):e230175. PubMed ID: 38573331
[No Abstract] [Full Text] [Related]
2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
[TBL] [Abstract][Full Text] [Related]
6. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
7. Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data.
Ton TGN; Pal N; Trinh H; Mahrus S; Bretscher MT; Machado RJM; Sadetsky N; Chaudhary N; Lu MW; Riely GJ
Clin Cancer Res; 2022 Jul; 28(13):2844-2853. PubMed ID: 35511917
[TBL] [Abstract][Full Text] [Related]
8. Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).
Vansteenkiste J; Barlesi F; Waller CF; Bennouna J; Gridelli C; Goekkurt E; Verhoeven D; Szczesna A; Feurer M; Milanowski J; Germonpre P; Lena H; Atanackovic D; Krzakowski M; Hicking C; Straub J; Picard M; Schuette W; O'Byrne K
Ann Oncol; 2015 Aug; 26(8):1734-40. PubMed ID: 25939894
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
[TBL] [Abstract][Full Text] [Related]
10. Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials.
Huang LT; Cao R; Wang YR; Sun L; Zhang XY; Guo YJ; Zhao JZ; Zhang SL; Jing W; Song J; Han CB; Ma J
BMC Cancer; 2021 Apr; 21(1):426. PubMed ID: 33865364
[TBL] [Abstract][Full Text] [Related]
11. Emulating Randomized Controlled Trials with Hybrid Control Arms in Oncology: A Case Study.
Sengupta S; Ntambwe I; Tan K; Liang Q; Paulucci D; Castellanos E; Fiore J; Lane S; Micsinai Balan M; Viraswami-Apanna K; Sethuraman V; Samant M; Tiwari R
Clin Pharmacol Ther; 2023 Apr; 113(4):867-877. PubMed ID: 36606735
[TBL] [Abstract][Full Text] [Related]
12. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).
Zhou C; Wu YL; Chen G; Feng J; Liu XQ; Wang C; Zhang S; Wang J; Zhou S; Ren S; Lu S; Zhang L; Hu C; Hu C; Luo Y; Chen L; Ye M; Huang J; Zhi X; Zhang Y; Xiu Q; Ma J; Zhang L; You C
Ann Oncol; 2015 Sep; 26(9):1877-1883. PubMed ID: 26141208
[TBL] [Abstract][Full Text] [Related]
13. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
Pirker R; Pereira JR; von Pawel J; Krzakowski M; Ramlau R; Park K; de Marinis F; Eberhardt WE; Paz-Ares L; Störkel S; Schumacher KM; von Heydebreck A; Celik I; O'Byrne KJ
Lancet Oncol; 2012 Jan; 13(1):33-42. PubMed ID: 22056021
[TBL] [Abstract][Full Text] [Related]
14. Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.
Han K; Claret L; Sandler A; Das A; Jin J; Bruno R
BMC Cancer; 2016 Jul; 16():473. PubMed ID: 27412292
[TBL] [Abstract][Full Text] [Related]
15. Conditional borrowing external data to establish a hybrid control arm in randomized clinical trials.
Li H; Tiwari R; Li QH
J Biopharm Stat; 2022 Nov; 32(6):954-968. PubMed ID: 35067183
[TBL] [Abstract][Full Text] [Related]
16. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
Johnson BE; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Lin CY; Marsland T; Patel T; Polikoff J; Rubin M; White L; Yang JC; Bowden C; Miller V
J Clin Oncol; 2013 Nov; 31(31):3926-34. PubMed ID: 24101054
[TBL] [Abstract][Full Text] [Related]
17. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.
Barlesi F; Scherpereel A; Gorbunova V; Gervais R; Vikström A; Chouaid C; Chella A; Kim JH; Ahn MJ; Reck M; Pazzola A; Kim HT; Aerts JG; Morando C; Loundou A; Groen HJ; Rittmeyer A
Ann Oncol; 2014 May; 25(5):1044-52. PubMed ID: 24585722
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.
Shah M; Winfree KB; Peterson P; Gruschkus SK; Eaddy M; Green MR
Lung Cancer; 2013 Oct; 82(1):121-7. PubMed ID: 23973203
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data.
Wilkinson S; Gupta A; Scheuer N; Mackay E; Arora P; Thorlund K; Wasiak R; Ray J; Ramagopalan S; Subbiah V
JAMA Netw Open; 2021 Oct; 4(10):e2126306. PubMed ID: 34618040
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer.
Bagley SJ; Talento S; Mitra N; Meropol NJ; Cohen RB; Langer CJ; Vachani A
J Natl Compr Canc Netw; 2019 May; 17(5):469-477. PubMed ID: 31085759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]